Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADZENYS ER vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ADZENYS ER is a central nervous system (CNS) stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Attention Deficit Hyperactivity Disorder (ADHD)
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
Adults: Initial 5-10 mg orally once daily; titrate in 5-10 mg increments weekly to optimal response; max 60 mg/day.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
6-8 hours in adults; in children 3-6 hours, requiring twice-daily dosing for sustained effect
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Metabolized primarily by hepatic esterases and cytochrome P450 (CYP) enzymes, including CYP2D6.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
70% renal (30% unchanged, 40% as metabolites), 30% fecal/biliary
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
97% bound to albumin and α1-acid glycoprotein
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
4.6-6.8 L/kg, indicating extensive tissue distribution, particularly in brain and adipose tissue
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Oral: 95% ± 10%; rectal: 80% ± 15%
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
GFR 30-89 m L/min: No adjustment. GFR <30 m L/min: Not recommended.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Not recommended.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
Children ≥6 years: Initial 5-10 mg orally once daily; titrate weekly by 5-10 mg; max 1 mg/kg/day or 60 mg/day, whichever is lower.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
Initiate at 5 mg once daily; titrate cautiously; monitor for cardiovascular effects and insomnia.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including ADZENYS ER, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Serious cardiovascular events: Sudden death, stroke, and myocardial infarction have been reported in patients with pre-existing cardiac abnormalities.,Blood pressure and heart rate increase: Monitor regularly.,Psychiatric adverse reactions: May precipitate or exacerbate psychosis or mania.,Long-term suppression of growth in pediatric patients: Monitor height and weight.,Seizures: May lower seizure threshold in patients with history of seizures.,Peripheral vasculopathy: Including Raynaud's phenomenon.
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Known hypersensitivity to amphetamines or other components of ADZENYS ER,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI,Agitated states,History of drug abuse,Cardiovascular disease including hypertension, arteriosclerosis, hyperthyroidism, glaucoma
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
High-fat meals can significantly delay and reduce the absorption of Adzenys ER; the time to peak concentration (Tmax) may be prolonged by approximately 1 hour and peak concentration (Cmax) reduced by about 38%. It is recommended to take Adzenys ER on an empty stomach (at least 1 hour before or 2 hours after a meal) to ensure consistent effect. Avoid alcohol while taking this medication, as it may increase the risk of cardiovascular side effects and impair judgment. No other specific food interactions are known, but patients should maintain a balanced diet to manage potential appetite suppression common with amphetamines.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
First trimester: Inadequate human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Chronic use may lead to neonatal withdrawal syndrome (hyperactivity, irritability, poor feeding) and reduced fetal growth. Avoid in first trimester unless benefit outweighs risk; use lowest effective dose in later trimesters.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Excreted in breast milk; M/P ratio approximately 2.6. Irritability and weight loss reported in nursing infants. Not recommended unless benefit outweighs risk.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
Clearance increased by approximately 30% in third trimester; may require dose escalation. Postpartum dose reduction may be needed to avoid toxicity. Individual titration based on clinical response and tolerability.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
Adzenys ER is an extended-release oral suspension of amphetamine (mixed salts) for ADHD. It provides a rapid onset (within 1 hour) and sustained effect over 10-12 hours. The suspension must be shaken vigorously for at least 10 seconds before each use. Dose titration should be guided by efficacy and tolerability, starting at 6.3 mg once daily in the morning for children 6-12 years. Avoid administration with high-fat meals as they may delay absorption (Cmax reduced by ~38%). Monitor for cardiovascular effects: heart rate, blood pressure, and potential for sudden death in patients with structural cardiac abnormalities. Use cautiously in patients with pyschosis, bipolar disorder, hypertension, hyperthyroidism, glaucoma, or history of drug abuse. Discontinue if agitation, aggression, or manic symptoms emerge. Drug holidays (weekend or holiday breaks) may be considered to assess need and reduce tolerance.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Take Adzenys ER exactly as prescribed, once daily in the morning; do not take in the afternoon or evening to avoid insomnia.,Shake the bottle vigorously for at least 10 seconds before each use; use the provided oral syringe to measure the correct dose.,Do not mix the medication with food or liquids; take it directly from the syringe.,Avoid taking with high-fat meals, as they may delay and reduce the drug's effect; take on an empty stomach if possible.,Store at room temperature (20-25°C); protect from light and moisture. Discard any unused portion after 30 days of opening.,Notify your doctor immediately if you experience chest pain, shortness of breath, fainting, or palpitations.,This medication has a high potential for abuse; do not share it with others and keep in a safe place.,Inform your doctor about all other medications, including OTC drugs and supplements, especially MAOIs (avoid within 14 days), antihypertensives, and SSRIs.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADZENYS ER vs ALFENTA, answered by our medical review team.
ADZENYS ER is a CNS Stimulant that works by ADZENYS ER is a central nervous system (CNS) stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADZENYS ER and ALFENTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADZENYS ER is: Adults: Initial 5-10 mg orally once daily; titrate in 5-10 mg increments weekly to optimal response; max 60 mg/day.. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADZENYS ER and ALFENTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADZENYS ER is classified as Category C. First trimester: Inadequate human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Chronic use may lead to neonata. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.